The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
890
February 19, 1993
View Complete Issue         Table of Contents 2019 
Oxaprozin for Arthritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Oxaprozin for Arthritis
February 19, 1993 (Issue: 890)
Oxaprozin (Daypro -Searle), a propionic acid-derivative nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for once-daily treatment of rheumatoid arthritis and osteoarthritis. Some of the NSAIDs...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Oxaprozin for Arthritis
Article code: 890a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.